Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $27.00.

NRIX has been the subject of several research reports. Royal Bank of Canada increased their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, July 12th. Needham & Company LLC lowered their price objective on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. JPMorgan Chase & Co. upped their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Barclays lifted their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, HC Wainwright upped their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th.

Read Our Latest Research Report on Nurix Therapeutics

Insiders Place Their Bets

In other news, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares in the company, valued at $546,680.16. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the transaction, the chief financial officer now directly owns 54,479 shares in the company, valued at $1,126,080.93. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,815 shares of company stock worth $1,424,931 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC lifted its position in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in Nurix Therapeutics by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after buying an additional 1,766 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in Nurix Therapeutics by 3.7% during the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after acquiring an additional 1,820 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after acquiring an additional 3,424 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after acquiring an additional 3,793 shares during the last quarter.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $21.54 on Thursday. Nurix Therapeutics has a fifty-two week low of $4.22 and a fifty-two week high of $26.31. The company’s 50-day moving average is $23.18 and its 200 day moving average is $18.97. The company has a market capitalization of $1.06 billion, a P/E ratio of -7.38 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last released its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. As a group, research analysts predict that Nurix Therapeutics will post -2.95 earnings per share for the current year.

Nurix Therapeutics Company Profile

(Get Free Report

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Recommended Stories

Analyst Recommendations for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.